CASC8 and pancreatic adenocarcinoma: Four sARLNRs (Z97832.2, CASC8, PAN3-AS1 and AC015660.1) among the 7 sARLNRs were used to establish the ARRS, by which PAAD patients were separated into the high-risk group and the low-risk group (Figure 2A).